Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system☆
References (20)
- et al.
Protein profile in multiple sclerosis
- et al.
HLA antigens in multiple sclerosis
Neurology (Minneap.)
(1976) - et al.
Dokumentation klinischer Befunde
- et al.
Erfassung von neurologisch relevanten Labordaten mit einem kombinierten Klartext-Markierungsbeleg
Z. Neurol.
(1974) - et al.
Complement-dependent cytotoxic activity against measles virus in multiple sclerosis
J. Neurol.
(1977) - et al.
Nationwide survey of multiple sclerosis in Japan
Neurology (Minneap.)
(1975) On the evaluation of disability in multiple sclerosis
Neurology (Minneap.)
(1961)- et al.
Studies on natural history of multiple sclerosis
Acta neurol. scand.
(1968) - et al.
Multiple Sclerosis
(1973) The benign form of multiple sclerosis
Brain
(1961)
Cited by (82)
Association of circulating anti-CD64 IgM levels with favourable long-term clinical outcomes in multiple sclerosis patients
2019, Journal of NeuroimmunologyCitation Excerpt :There is wide evidence that subgroups of patients with multiple sclerosis (MS) may have a benign course (Lublin et al., 2014; Lublin and Reingold, 1996) or at least be clinically stable in a frequency ranging from 5 to 40% (Hutchinson, 1986; Pittock et al., 2004; Poser and Wikstrom, 1979).
RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis
2017, Journal of NeuroimmunologyCitation Excerpt :Patients with benign MS reflect the capacity to withstand the deteriorating processes of the disease and the ability to endure or recover quickly from the acute demyelinating inflammatory insults. Thus, these patients are not harmed by the ongoing pathologic processes of myelin and neuronal loss that characterize active MS (Gauthier et al., 2009; Glad et al., 2009; Hawkins and McDonnell, 1999; Pittock and Rodriguez, 2008; Poser et al., 1979; Ramsaransing and De Keyser, 2007). Recently, using high throughput peripheral blood gene expression microarray analysis we identified a specific signature that characterizes benign MS (Achiron et al., 2012).
Contraceptive use among women with multiple sclerosis: a systematic review
2016, ContraceptionCitation Excerpt :Excluded studies were mainly review papers and papers not relevant to our key question. Three studies were excluded because it was unclear if contraceptive use occurred after MS diagnosis [25–27]. Each of the four included studies examined OCs, two of which specified the type as combined oral contraceptives (COCs) [20,22].
Pathophysiological background and clinical characteristics of sleep disorders in multiple sclerosis
2013, Clinical Neurology and NeurosurgeryCitation Excerpt :Traditionally, MS is viewed as a T-cell driven immune disorder in which primary dysregulation of peripheral immune responses leads to a CNS-directed autoimmune disease and inflammatory tissue injury which can also trigger degenerative process, a pathological hallmark of clinical progression of neurological impairment. Besides T-cells there are other mediators of cell immunity such as macrophage, reactive microglia, NK cells, NK T cells, gamma/delta T cells and mediator of hummoral immunity like antigen-specific CNS-reactive antibodies, proinflammatory cytokines, nitric oxide and reactive oxygen species, leukotrienes, plasminogen activators and matrixmetallo proteinases (MMPs) [1] Symptoms and sings of MS depend on the location of CNS affected [2] but fatigue is far most common symptom of MS [3]. Fatigue in MS can be caused either by multiple sclerosis per se or it can be result of other frequently encountered disturbances in MS such as depression, sleepiness, pain or due to various medication in the latter case it is usually called secondary fatigue [4].
Polymerase I pathway inhibitor ameliorates experimental autoimmune encephalomyelitis
2013, Journal of NeuroimmunologyCitation Excerpt :Patients with benign MS reflect the capacity to withstand the deteriorating processes of the disease and the ability to endure or recover quickly from the acute demyelinating inflammatory insult. Thus, these patients are not harmed by the ongoing pathologic processes of neuronal and myelin loss that characterize active MS (Poser et al., 1979; Hawkins and McDonnell, 1999; Ramsaransing and De Keyser, 2007; Pittock and Rodriguez, 2008; Glad et al., 2009). We have recently identified, using high throughput peripheral blood gene expression microarray analysis, a specific signature that characterizes benign MS (Achiron et al., 2012).
Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis
2013, Journal of NeuroimmunologyCitation Excerpt :Multiple sclerosis (MS) is an inflammatory disease of the central nervous system that mainly destroys myelin but also causes axonal damage (Compston and Coles, 2002). In several studies from different countries, 5 to 40% of patients have been classified as having a benign course (Poser et al., 1979; Hutchinson, 1986). Some patients may experience a long interval between the first and second or consecutive attacks, supporting the concept of stable disease.
- ☆
This work was supported by the Deutsche Forschungsgemeinschaft.
- ∗
Senior physician.
- ∗∗
Address: Department of Neurology, Haartmanink 4, 00290 Helsinki 29, Finland.